Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ACP1 | P24666 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14697144 | 0.84 | ALOX5 (0.57) | LMNAHPGDSMN1; SMN2ADORA1ADORA2A | |
| SCHEMBL8381387 | 0.84 | KDM4E (0.78) | LMNAHPGDSMN1; SMN2ADORA1ADORA2A | |
| SCHEMBL17931071 | 0.82 | TP53 (0.53) | LMNAHPGDSMN1; SMN2ADORA1ADORA2A | |
| SCHEMBL25982178 | 0.82 | NAMPT (0.61) | LMNAHPGDSMN1; SMN2ADORA1ADORA2A | |
| SCHEMBL14696938 | 0.82 | SMN1; SMN2 (0.65) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL955714 | 0.81 | SMN1; SMN2 (1.00) | LMNAHPGDSMN1; SMN2ADORA1KDM4E | |
| SCHEMBL10611075 | 0.81 | KDM4E (0.58) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31529381 | 0.81 | KDM4E (0.49) | LMNAHPGDSMN1; SMN2ADORA1ADORA2A | |
| SCHEMBL10610967 | 0.81 | SMN1; SMN2 (0.56) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL25982180 | 0.80 | NAMPT (0.59) | LMNAHPGDSMN1; SMN2ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145599-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MRJA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145599-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | IGF1R, IGFBP1, IGFBP2 | LMNA 978/4885HPGD 1604/4885SMN1; SMN2 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.